AAS
LXRX icon

Avantax Advisory Services’s Lexicon Pharmaceuticals LXRX Stock Holding History

Avantax Advisory Services’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$11.1K Hold
11,724
– – ﹤0.01% 2354
2025
Q1 		$5.4K Buy
+11,724
New +$7.4K ﹤0.01% 2225

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avantax Advisory Services's LXRX Position: Q2 2025 in Review

Avantax Advisory Services held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2025 at 11,724 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2354.

Avantax Advisory Services first reported a position in LXRX in Q1 2025 and has held it in 2 quarters since. 123 funds tracked by Wall St. Rank hold LXRX as of Q2 2025.

  • Avantax Advisory Services held 11,724 shares of Lexicon Pharmaceuticals worth $11.1K as of Q2 2025.
  • Avantax Advisory Services left its Lexicon Pharmaceuticals share count unchanged in Q2 2025.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #2354 holding.
  • Avantax Advisory Services first reported a position in Lexicon Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • 123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.